VPTDF - Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs
(TheNewswire)
Toronto, Ontario – TheNewswire - April 8, 2025 – VentripointDiagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announcedthat it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. Inthis role he will be providing leadership to the Company’s ongoingresearch, translational science, and clinical studies. Nicolas willreport directly to Hugh MacNaught, President and CEO.
Dr. Coutin was part of the partnering team at AbCellera which builtindustry-leading capabilities
through partnerships with the top tier of biotech and pharma industrypartners. His experience includes leading the Venture and coreprogramming team at Creative Destruction Lab, where, with his team, hedelivered an objectives-based program for massively scalable,seed-stage, science- and technology-based companies.
“Nic has experience and a strong understanding of translationalprograms.” said Ventripoint’s CEO Hugh MacNaught. “Hisexperience supporting the advancement of innovation from research tothe clinic will enable us to build stronger relationships with ourclinical advisors and collaborators.”
Coutin added: “Ventripoint’s decades of research and developmenthave positioned it become the new standard for rapidly and robustlymeasuring heart function. Strengthening the clinical-evidence basewill support broader clinical use of Ventripoint’s VMS+™ V4.0. Ilook forward to working with the team to expand the application ofthis differentiated technology to numerous cardiac indications.”
For further information, pleasecontact:
Hugh MacNaught
(604) 671-4201
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.